What are the new treatments for triple-negative and HER2-positive Breast Cancer?
Breast cancer treatment has evolved significantly, especially for aggressive subtypes like triple-negative breast cancer (TNBC) and HER2-positive breast cancer. For TNBC, new approaches combine chemotherapy with immunotherapy, and researchers are exploring targeted therapies based on tumor markers. For HER2-positive disease, neoadjuvant (pre-surgery) therapy often includes targeted drugs, and post-surgery options like trastuzumab emtansine (T-DM1) are used for patients with residual disease. These advances aim to improve outcomes and reduce recurrence.
What the research says
For triple-negative breast cancer (TNBC), chemo-immunotherapy has become a standard approach. The KEYNOTE-522 trial established pembrolizumab combined with platinum-based chemotherapy for high-risk early-stage TNBC 3. A case report of a rare triple-negative neuroendocrine breast cancer showed that a patient remained disease-free at 12 months after treatment with paclitaxel, cisplatin, and pembrolizumab 3. Additionally, NY-ESO-1, a cancer-testis antigen expressed in about 16% of TNBCs, is being studied as a target for immunotherapy, including adoptive cell therapy and peptide vaccines 6. The gut microbiome may also influence TNBC treatment response, and dietary modulation is an emerging strategy 4.
For HER2-positive breast cancer, neoadjuvant therapy often includes targeted agents like trastuzumab and pertuzumab, which can lead to high rates of pathologic complete response (pCR) 910. After surgery, for patients with residual disease, trastuzumab emtansine (T-DM1) is a standard option 7. Capecitabine is also used in certain settings 7. These targeted therapies have improved outcomes for HER2-positive disease 9.
Both subtypes benefit from biomarker-driven approaches. For TNBC, PD-L1 status and BRCA mutations guide immunotherapy and PARP inhibitor use 911. For HER2-positive disease, the HER2 receptor itself is the target. Ongoing research continues to refine these strategies, including the role of immunotherapy in HER2-positive breast cancer 11.
What to ask your doctor
- For triple-negative breast cancer: Is chemo-immunotherapy (e.g., pembrolizumab plus chemotherapy) appropriate for my stage and PD-L1 status?
- For triple-negative breast cancer: Should I be tested for NY-ESO-1 or other cancer-testis antigens to see if I might qualify for targeted immunotherapy trials?
- For HER2-positive breast cancer: Is neoadjuvant therapy with trastuzumab and pertuzumab recommended before surgery?
- For HER2-positive breast cancer: After surgery, if there is residual disease, is trastuzumab emtansine (T-DM1) an option for me?
- Are there any clinical trials available for my specific subtype that I should consider?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.